Ekso BionicsEKSO
EKSO
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
14% more funds holding
Funds holding: 28 [Q3] → 32 (+4) [Q4]
6.44% less ownership
Funds ownership: 24.82% [Q3] → 18.37% (-6.44%) [Q4]
60% less capital invested
Capital invested by funds: $6.2M [Q3] → $2.47M (-$3.73M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
128%
upside
Avg. target
$5
1,040%
upside
High target
$9
1,952%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Ben Haynor 44% 1-year accuracy 4 / 9 met price target | 128%upside $1 | Buy Maintained | 4 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 46 / 198 met price target | 1,952%upside $9 | Buy Reiterated | 4 Mar 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
3 weeks ago
Ekso Bionics Holdings, Inc. (EKSO) Q4 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Li Chen - H.C. Wainwright Ben Haynor - Lake Street Capital Operator Greetings, and welcome to the Ekso Bionics Fourth Quarter 2024 Financial Results Conference Call.

Neutral
GlobeNewsWire
3 weeks ago
Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results
SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024.

Neutral
GlobeNewsWire
1 month ago
Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.

Neutral
GlobeNewsWire
1 month ago
NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry
Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States

Neutral
GlobeNewsWire
4 months ago
Ekso Bionics to Showcase Its Device Technology in ‘AI for Good' Webinar on Tuesday, November 19
SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an ‘AI for Good' webinar.

Neutral
GlobeNewsWire
4 months ago
Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select Conference
SAN RAFAEL, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating at the 15th Annual Craig-Hallum Alpha Select Conference taking place in New York on Tuesday, November 19, 2024.

Negative
Zacks Investment Research
4 months ago
Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.24 per share a year ago.

Neutral
Seeking Alpha
4 months ago
Ekso Bionics Holdings, Inc. (EKSO) Q3 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2024 Financial Results Call.

Neutral
GlobeNewsWire
4 months ago
Ekso Bionics Announces Third Quarter 2024 Financial Results
SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024.

Neutral
GlobeNewsWire
5 months ago
Ekso Bionics to Report Third Quarter 2024 Financial Results on October 28, 2024
SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Charts implemented using Lightweight Charts™